Real-world safety and effectiveness of radium-223 (223Ra) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated in the US: The non-interventional REASSURE study

被引：0
|
作者：
Song, Daniel Y.
George, Saby
Zimberg, Shawn
Nordquist, Luke T.
Tomaszewski, Jeffrey
Conti, Peter S.
Meltzer, Jeffrey
Verholen, Frank
Schmall, Anja
Higano, Celestia S.
Sartor, A. Oliver
机构：
[1] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD USA
[2] Roswell Park Canc Inst, Buffalo, NY USA
[3] Adv Radiat Ctr New York, Lake Success, NY USA
[4] GU Res Network, Urol Canc Ctr, Omaha, NE USA
[5] MD Anderson Canc Ctr Cooper, Div Urol, Camden, NJ USA
[6] USC, Keck Sch Med, Mol Imaging Ctr, Los Angeles, CA USA
[7] Bayer Healthcare Pharmaceut Inc, Whippany, NJ USA
[8] Bayer Consumer Care, Basel, Switzerland
[9] Univ Washington, Seattle, WA 98195 USA
[10] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[11] Tulane Univ, Sch Med, Tulane Canc Ctr, 1430 Tulane Ave, New Orleans, LA 70112 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5050
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Combination treatment with radium-223 (223Ra) and enzalutamide (enza) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the REASSURE study
    Tombal, B.
    Goebell, P. J.
    Shore, N. D.
    George, D. J.
    Pinto, A.
    Sartor, O.
    Meltzer, J.
    Verholen, F.
    Schmall, A.
    Saad, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S984 - S984
  • [2] Safety outcomes and pain responses in the REASSURE observational study of radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Conti, Peter
    George, Saby
    Tomaszewski, Jeffrey
    Song, Daniel
    Harshman, Lauren
    Nordquist, Luke
    Sandstrom, Per
    Bayh, Inga
    Babajanyan, Svetlana
    Sartor, Oliver
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [3] Alkaline phosphatase (ALP) decline and pain response as markers for overall survival (OS) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (223Ra) in the REASSURE study
    O'Sullivan, J.
    Heinrich, D.
    Marcos, E. Castro
    George, S.
    Song, D. Y.
    Dizdarevic, S.
    Baldari, S.
    Essler, M.
    de Jong, I. J.
    Lastoria, S.
    Hammerer, P. G.
    Tombal, B.
    James, N. D.
    Verholen, F.
    Meltzer, J.
    Sandstroem, P.
    Sartor, O.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1181 - S1181
  • [4] Fracture risk in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra 223)
    Hijab, A.
    Tunariu, N.
    Tovey, H.
    Alonzi, R.
    Tree, A.
    Staffurth, J.
    Blackledge, M.
    Padhani, A. R.
    Stidwill, H.
    Finch, J.
    Chatfield, P.
    Perry, S.
    Koh, D-M.
    Hall, E.
    Parker, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S539 - S539
  • [5] Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
    Palmedo, H.
    Eschmann, S.
    Werner, A.
    Selinski, I.
    Moellers, M-O.
    Kalinovsky, J.
    Benson, A.
    Poeppel, T.
    ANNALS OF ONCOLOGY, 2019, 30 : 336 - 336
  • [6] Pain efficacy with radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the PARABO observational study
    Palmedo, H.
    Ahmadzadehfar, H.
    Eschmann, S.
    Selkinski, I.
    Straube, F.
    Niesen, A.
    Schoenberger, J.
    Barsegian, V.
    Liepe, K.
    Mottaghy, F. M.
    Guan, R.
    Pinkert, J.
    Buetikofer, S.
    Herrmann, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S641 - S641
  • [7] Real-world utilization of radium-223 (Ra-223) for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A US tertiary oncology center analysis
    McKay, Rana R.
    Silver, Rebecca
    Bhak, Rachel
    Korves, Caroline
    Cheng, Mu
    Appukkuttan, Sreevalsa
    Simmons, Stacey J.
    Duh, Mei Sheng
    Taplin, Mary-Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [8] Alkaline phosphatase (ALP) decline and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the REASSURE study.
    James, Nicholas D.
    Heinrich, Daniel
    Castro, Elena
    George, Saby
    Song, Daniel Y.
    Dizdarevic, Sabina
    Baldari, Sergio
    Essler, Markus
    De Jong, Igle Jan
    Lastoria, Secondo
    Hammerer, Peter G.
    Meltzer, Jeffrey
    Sandstrom, Per
    Verholen, Frank
    Tombal, Bertrand F.
    O'Sullivan, Joe M.
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] Pain efficacy with radium-223 (Ra-223) in the REASSURE global, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC)
    Higano, C. S.
    Dizdarevic, S.
    Sundar, S.
    Agarwal, N.
    Essler, M.
    Song, D.
    George, S.
    Shore, N. D.
    Kurtinecz, M.
    Verholen, F.
    Sandstrom, P.
    Sartor, O.
    George, D. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S640 - S641
  • [10] Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC)
    Higano, Celestia S.
    Saad, Fred
    Sartor, A. Oliver
    Miller, Kurt
    Conti, Peter
    George, Daniel J.
    Sternberg, Cora N.
    Shore, Neal D.
    Sade, Juan Pablo
    Bellmunt, Joaquim
    Smith, Matthew Raymond
    Logothetis, Christopher
    Verholen, Frank
    Kalinovsky, Jan
    Bayh, Inga
    Tombal, Bertrand F.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345